Hepatitis C

Approx. Rs 6,300 / BottleGet Latest Price

The active components Sofosbuvir and Velpatasvir.  It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Myhep All tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Myhep All tablet or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases. 

• To treat chronic hepatitis C (HCV) infection.

Therapeutic Effects of Myhep All Tablet

Sofosbuvir is a direct-acting antiviral drug (DAA) that inhibits the replication of the HCV virus by targeting a specific protein necessary for viral replication. Velpatasvir is also a DAA that works by blocking the action of another protein involved in the HCV replication process.

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Myhep All tablet, reducing effectiveness by causing undesirable side effects.

Additional Information: